DCAT Week ’24, which took place March 18-21 in New York City, is the premiere industry event for the Global Bio/Pharmaceutical Manufacturing Value Chain. As sponsors, CordenPharma had a successful week of meetings and connections with existing and new customers and participated in the Member Company Forum with an announcement by Dr. Stephen Houldsworth on the large ongoing capex expansions across our technology platforms in 2023 and 2024.
This video taken at DCAT features our Platform Directors giving a highlight of their platform in 2024:
Dr. Stephen Houldsworth, Senior VP, Global Head of Platform Management & Marketing, speaks about the small to large-scale capacity of the Small Molecules Platform.
Dr. Brittany L Hayes, Director, Global Highly Potent & Oncology Platform, updates on expanded Oral Solid Dosage manufacturing capabilities and new technologies for for Bioavailability Enhancement, including Oral Peptide Delivery.
Dr. Matthieu Giraud, Senior Director, Global Lipids & Carbohydrates Platform, gives an update on specialized lipids tailored for mRNA delivery, including new LNP Starter Kits for optimizing LNP Formulation.
Dr. Stephane Varray, Director, Global Peptides Platform, informs on expanded early-phase GMP Peptide manufacturing targeted for companies with INDs, as well as seamlessly integrated Injectable Manufacturing services.
Dr. John Cameron, Director, Global Injectables Platform, speaks on our new LNP Formulation area, and expanded Sterile Injectable Fill & Finish lines, including packaging.
Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.